Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

AN2 Therapeutics, Inc. - Common Stock (NQ:ANTX)

1.210 +0.030 (+2.54%)

Streaming Delayed Price Updated: 11:01 AM EST, Jan 21, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	24,652
Open	1.160
Bid (Size)	1.200 (200)
Ask (Size)	1.250 (500)
Prev. Close	1.180
Today's Range	1.141 - 1.220
52wk Range	1.000 - 1.550
Shares Outstanding	21,928,452
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease

January 12, 2026

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights

November 12, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

Performance

YTD	+9.0%	+9.0%
1 Month	+9.0%	+9.0%
3 Month	N/A	N/A
6 Month	+9.0%	+9.0%
1 Year	-4.7%	-4.7%

More News

AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)

November 10, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference

November 06, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

September 23, 2025

Via Benzinga

AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights

August 12, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease

August 12, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease

July 23, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole

June 30, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference

May 29, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights

May 13, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 01, 2025

Via Benzinga

AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline

May 01, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference

April 30, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights

March 25, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference

March 03, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease

February 24, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Participate at Upcoming Investor Conferences

February 20, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

January 29, 2025

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Participate at Upcoming Investor Conferences

November 14, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

November 13, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

October 17, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket ↗

October 03, 2024

Via Benzinga

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

August 28, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

August 16, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is AN2 Therapeutics, Inc. - Common Stock publicly traded?

Yes, AN2 Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does AN2 Therapeutics, Inc. - Common Stock trade on?

AN2 Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for AN2 Therapeutics, Inc. - Common Stock?

The ticker symbol for AN2 Therapeutics, Inc. - Common Stock is ANTX on the Nasdaq Stock Market

What is the current price of AN2 Therapeutics, Inc. - Common Stock?

The current price of AN2 Therapeutics, Inc. - Common Stock is 1.210

When was AN2 Therapeutics, Inc. - Common Stock last traded?

The last trade of AN2 Therapeutics, Inc. - Common Stock was at 01/21/26 11:01 AM ET

What is the market capitalization of AN2 Therapeutics, Inc. - Common Stock?

The market capitalization of AN2 Therapeutics, Inc. - Common Stock is 26.53M

How many shares of AN2 Therapeutics, Inc. - Common Stock are outstanding?

AN2 Therapeutics, Inc. - Common Stock has 27M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.